Bharat Book

Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies

Press Release   •   Dec 04, 2013 17:33 IST

Dec 4, 2013 : Bharat Book Bureau presents the new report, on ''Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of December 2012.

Product description
The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies provides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules. The cumulated sales volume of therapeutic antibodies for which biosmilar antibodies are in the R&D pipeline was as high as US$ 54.7 bln in the year 2011 with double digit growth rates of many representative of them:

Rituxan/MabThera
Arzerra
Erbitux
Vectibix
Herceptin
Avastin
Lucentis
Enbrel
Remicade
Humira
Cimzia
Simponi
Actemra/RoActemra
ReoPro
Campath
Orencia
Tysabri
Xolair
Synagis
Prolia/Xgeva
Soliris
Stelara
Zenapax

More than 140 biosimilar antibodies are in the pipeline with the first molecules approved in non-regulated markets. Ther regulation of the development of biosimilar antibodies in the European Union has facilitated the submission of an MAA of a first biosimilar antibody from a Korean company.

The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:

CD20
Her2
VEGF
TNF
EGF-R
CD52
GPIIb/IIIa
B7.1/B7.2 (CD80/CD86)
IL-6R
Alpha4/beta1/7 integrin
IgE
RSV
RANKL
Complement C5
IL-12/IL-23
CD25 (IL-2R)

Competitor projects are listed in a tabular format providing information on:

Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.

Table of Contents:
CD20 Antibodies
1. Marketed CD20 Antibodies & Sales
Rituxan/MabThera Pipeline & Sales
Arzerra Pipeline & Sales
Zevalin Pipeline & Sales
Bexxar
2. Biosuperior CD20 Antibodies
Bispecific CD20 Antibodies
3. Biosimilar CD20 Antibodies
Rituximab (Erbitux) Biosimilars
Ofatumumab (Arzerra) Biosimilars

EGF-R Antibodies
1. Marketed EGF-R Antibodies & Sales
Erbitux Pipeline & Sales
Vectibix Pipeline & Sales
Nimotuzumab Pipeline
2. Biosuperior EGF-R Antibodies
3. Biosimilar EGF-R Antibodies
Cetuximab (Erbitux) Biosimilars
Panitumumab (Vectibix) Biosimilars

Her2 Antibodies
1. Marketed Her2 Antibodies & Sales
Herceptin Pipeline & Sales
Next Generation Herceptin: Pertuzumab Pipeline
2. Biosuperior Her2 Antibodies
T-DM1 Pipeline
Other Her2 Antibody-Drug Conjugates
Her2 Bispecific Antibodies
Engineered Her2 Antibodies
Imaging Her2 Antibodies
3. Biosimilar Her2 Antibodies
Trastuzumab (Herceptin) Biosimilars

VEGF Antibodies: Avastin
1. Marketed VEGF Antibody & Sales
Avastin Pipeline & Sales
2. Biosuperior VEGF Antibodies
Anti-VEGF Antibody Pipeline
Anti-VEGF-R Antibody Pipeline
Bispecific Anti-VEGF Pipeline
3. Biosimilar VEGF Antibodies
Bevacizumab (Avastin) Biosimilars

VEGF Antibodies: Lucentis
1. Marketed VEGF Antibody & Sales
Lucentis Pipeline & Sales
2. Biosuperior VEGF Antibodies
Next Generation Lucentis Pipeline
3. Biosimilar VEGF Antibodies
Ranibizumab (Lucentis) Biosimilars

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/competitor-analysis-biosimilar-and-biosuperior-therapeutic-antibodies.html

Related link : www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html


About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com 
Website: www.bharatbook.com 
Follow us on twitter: https://twitter.com/researchbook 
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau 
Our Blog : http://blog.bharatbook.com/ 


Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.